New Zealand medical cannabis producer Rua Bioscience has signed its largest export agreement to date, securing a two-year sales and distribution deal with one of the United Kingdom's biggest private medicinal cannabis clinic and distribution businesses.

The agreement is expected to generate more than NZ$10 million in revenue over its initial term and will see Rua supply New Zealand-grown medical cannabis flower into Britain's largely import-dependent private market.

Rua said the partnership gives it immediate access to an established clinic network, pharmacy relationships and prescriber connections that would have taken years to build independently. At the request of its commercial partner, the UK company has not been named publicly while it completes its own communications.

Why the UK market matters

Britain's medical cannabis programme has expanded quickly since prescribing was opened to specialist doctors in November 2018, though NHS access remains limited and most patients obtain treatment privately.

Rua cited industry estimates putting the UK market at around £226 million in 2025, representing year-on-year growth of 103 per cent. Import volumes reached an estimated 30 tonnes last year, up from roughly 14 tonnes in 2024 and nearly three times the level recorded in 2022.

The company said between 90,000 and 94,000 patients are now thought to access medical cannabis through private clinics, against a Department of Health and Social Care estimate of up to three million potentially eligible patients. That gap underscores both the commercial opportunity and the scale of unmet demand that import-led suppliers are targeting.

What Rua is supplying

Under the deal, Rua will export medical cannabis flower cultivated in Aotearoa New Zealand using genetics drawn from the country's legacy cannabis market. The company has positioned those genetics as a differentiator in higher-value international markets.

"Rua will supply medical cannabis flower cultivated in Aotearoa, New Zealand using genetics sourced from New Zealand's legacy market," chief executive Paul Naske said. "Our strategy has always been to connect Rua's differentiated New Zealand genetics with high-value international markets."

Naske described the agreement as a major milestone in Rua's international growth strategy and said it validated the quality of the company's New Zealand-grown product offering. He added that the partnership positioned Rua alongside leading global medical cannabis businesses and represented an important development for shareholders.

A capital-light export model

Rua has pursued a strategy focused on supplying differentiated genetics to overseas markets rather than building full-scale infrastructure in every territory. The UK agreement adds to its commercial footprint in Germany, Australia, Canada, Czechia and New Zealand.

For British patients, the deal is unlikely to change prescribing rules or NHS access. It is instead a sign of how the private import market continues to scale, with overseas cultivators partnering established UK clinic groups to place flower on pharmacy shelves.

What to watch next

The unnamed UK partner is expected to make its own announcement in due course, which may clarify which clinic group and product lines are involved. Investors and patients alike will also be watching whether the agreement leads to new flower brands entering the market or simply expands supply within an existing distribution network.

For the wider UK sector, the transaction reinforces a familiar pattern: rapid private-market growth, heavy reliance on imports, and international producers treating Britain as one of the world's most commercially significant medical cannabis destinations.

Reporting based on a Rua Bioscience company announcement, 13 July 2026.